IL2 and neoplasm: Second, the release of some cytokines, such as IL-2 and IL-15, as well as subsequently stimulated IFN-γ, can stimulate the enhancement of avelumab-triggered cytokine production and degranulation in NK cells while increasing lytic activity against tumor cells (67).